KABRADG.BO · BSE
KABRA DRUGS LTD.
₹19.13
+0.05% (+₹0.01)
Prev. close
₹19.12
Volume
48,075
As of
24 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About KABRA DRUGS LTD.
Aanjaay Industries Limited engages in the manufacture and trade of pharmaceutical products. Its product portfolio includes cardiovascular, anti-infective, oncology, gastroenterologic, hormonal, and miscellaneous drugs; critical care injectibles, pre-filled syringes, and active pharmaceutical ingredients. The company was formerly known as Kabra Drugs Limited and changed its name to Aanjaay Industries Limited in July 2026. The company was incorporated in 1989 and is based in Chennai, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Kuniamuthur Nanjappan Anand
Headquarters
Chennai
Website
aanjaayind.comExchange
View on BSE ↗Key stats
Market cap
₹45.33 Cr
P/E ratio (TTM)
6.0
EPS (TTM)
₹3.20
Beta (1Y · daily vs NIFTY 50)
1.14
Beta (5Y · monthly vs NIFTY 50)
0.39
Shares float
1.93 Cr
EPS · quarter ended Jun 2026
₹0.90
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹0 | ₹0 | ₹0 | ₹92.74 Cr | |
| EBITDA | ₹-33.79 L | ₹-73.61 L | ₹-1.08 Cr | ₹5.82 Cr |
| ₹-33.79 L | ₹-73.61 L | ₹-1.09 Cr | ₹4.96 Cr | |
| Diluted EPS | ₹-0.77 | ₹-1.68 | ₹-0.99 | ₹2.09 |
Total expenses (as filed), Employee benefit expense, Other expenses have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| — | ₹70.36 L | ₹4.57 Cr | ₹25.23 Cr | ₹86.32 Cr | |
| — | ₹1.38 Cr | ₹1.71 Cr | ₹43.74 L | ₹56.91 L | |
| Stockholders' equity | — | ₹-73.10 L | ₹1.08 Cr | ₹24.65 Cr | ₹29.61 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, Fixed assets, Total debt, Long-term debt, Current (short-term) debt, Others, Stockholders' equity have filed figures for only some of the years shown — the missing years are left blank rather than estimated. Inventory shows ₹0 for 2022-03-31, 2024-03-31, 2025-03-31, 2026-03-31 — this deck's own annual-report reading has no Inventory figure for this filer in any year shown (2022-03-31, 2024-03-31, 2025-03-31, 2026-03-31, 2023-03-31 alike); the ₹0 shown here comes from this filer's own reported data feed rather than this deck's own extraction, and is positively consistent with a filer that holds no physical inventory (typical for lenders and other financial-services companies) rather than a display default. 2023-03-31 has no Inventory figure reaching this deck at all — not shown as zero, not shown as positive — left blank rather than assumed to match the other years.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| ₹-35.44 L | ₹-20.85 L | ₹-4.71 Cr | ₹-9.47 Cr | |
| Investing cash flow | ₹0 | ₹0 | ₹-5.13 L | ₹-1.36 Cr |
| Financing cash flow | ₹35.61 L | ₹2.88 Cr | ₹23.39 Cr | ₹11.50 L |
| Capital expenditure | — | — | ₹-5.13 L | ₹-86.82 L |
| End cash position | ₹29,496 | ₹2.67 Cr | ₹21.30 Cr | ₹10.58 Cr |
Capital expenditure has filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.47 L Cr | ₹1,849.9 | 37.0 | 5.35 | 13.7% | 0.06 | +11.9% | +13.7% |
| Divi's Laboratories Limited | ₹2.55 L Cr | ₹9,602 | 87.2 | 15.24 | 15.3% | 0.00 | +12.3% | +60.5% |
| Torrent Pharmaceuticals Limited | ₹1.90 L Cr | ₹4,928.5 | 79.5 | 22.60 | 25.8% | 1.79 | +21.5% | +36.3% |
| Apollo Hospitals Enterprise Limited | ₹1.30 L Cr | ₹8,888.5 | 61.0 | 13.75 | 20.5% | 0.90 | +15.7% | +16.3% |
| Lenskart Solutions Limited | ₹1.19 L Cr | ₹676 | 180.7 | 13.61 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.17 L Cr | ₹1,180.3 | 26.1 | 4.31 | 18.6% | 0.46 | +18.4% | +13.9% |
| Cipla Limited | ₹1.12 L Cr | ₹1,399 | 33.2 | 3.24 | 11.3% | 0.02 | +2.1% | -9.0% |
| Laurus Labs Limited | ₹1.10 L Cr | ₹2,026.2 | 100.9 | 20.84 | 16.8% | 0.48 | +22.0% | +122.7% |
| Max Healthcare Institute Limited | ₹1.03 L Cr | ₹1,046 | 71.1 | 9.60 | 13.4% | 0.32 | +19.0% | -7.7% |
| Mankind Pharma Limited | ₹1.02 L Cr | ₹2,500 | 49.0 | 6.25 | 11.7% | 0.39 | +17.0% | -1.2% |
| Dr. Reddy's Laboratories Limited | ₹1.01 L Cr | ₹1,200.4 | 30.5 | 2.68 | 11.4% | 0.21 | +3.2% | -7.5% |
| KABRA DRUGS LTD. | ₹45.33 Cr | ₹19.12 | 6.0 | 1.53 | 16.7% | 0.02 | — | +0.8% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 20
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.